The journey doesn’t end with a diagnosis. AI is helping patients move faster toward new treatments, clinical trials, and ...

There are subtle but significant differences in the morphology and biochemistry of the eye between men and women. These differences may affect disease susceptibility, symptoms and progression, ...

Insulin resistance (IR) is a crucial factor in metabolic disorders like non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS), ...

Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based ...

AI guidance for clinicians aimed at reducing the spread of Clostridioides difficile—a bacteria that can be deadly for sick ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in participants.

Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and ...

About 30% of all respiratory tract infections are caused by coronaviruses, leading to widespread illnesses and, in some cases, to epidemic and even pandemic outbreaks, as we experienced with the COVID ...

Recent studies assessed artificial intelligence (AI) assistance tools in their ability to provide quality medical recommendations for patients.

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.